HKBU and Cornell University develop novel nano-carrier that increases efficacy of breast cancer Chinese medicine treatment

11 May 2021

With the support of the Vincent and Lily Woo Foundation, HKBU researchers have collaborated with Cornell University and developed a novel targeted therapy for triple-negative breast cancer (TNBC) that uses a specially-designed nano-carrier to deliver the Chinese medicine compound gambogic acid (GA). The invention enhances the anti-cancer effect of GA and reduces its damage to off-target organs. It has the potential to become a more effective therapeutic option for TNBC.

The study was led by Professor Bian Zhaoxiang, Director of the School of Chinese Medicine’s Clinical Division and Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies, and Dr. Kwan Hiu Yee, Assistant Professor of the School’s Teaching and Research Division, in collaboration with the research team of Professor Chu Chih Chang at Cornell University. The research findings have been published in the international medical journal Frontiers in Oncology.

“The application of nanotechnology in this study modernises the delivery of Chinese medicine, thereby enhancing its therapeutic efficacy. We believe that our nano-carriers have great clinical potential to treat TNBC and other types of cancer,” said Professor Bian. Please click here for more details.